Cargando…
New developments in atherosclerosis: clinical potential of PCSK9 inhibition
Pro-protein convertase subtilisin/kexin type 9 (PCSK9) is a secreted 692-amino acid protein that binds surface low-density lipoprotein (LDL) receptor (LDLR) and targets it toward lysosomal degradation. As a consequence, the number of LDLRs at the cell surface is decreased, and LDL-cholesterol (LDL-C...
Autores principales: | Giunzioni, Ilaria, Tavori, Hagai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4554462/ https://www.ncbi.nlm.nih.gov/pubmed/26345307 http://dx.doi.org/10.2147/VHRM.S74692 |
Ejemplares similares
-
Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
por: Shapiro, Michael D., et al.
Publicado: (2019) -
Insights into the kinetics and dynamics of the furin-cleaved form of PCSK9
por: Oleaga, Carlota, et al.
Publicado: (2020) -
PCSK9 and Atherosclerosis - Lipids and Beyond
por: Shapiro, Michael D., et al.
Publicado: (2017) -
An Update on the Role of PCSK9 in Atherosclerosis
por: Yurtseven, Ece, et al.
Publicado: (2020) -
Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis
por: Punch, Emily, et al.
Publicado: (2022)